How much funding has Purespring raised?

Purespring has raised $165.0M in total funding, most recently a Series B round.

Who are Purespring's investors?

Purespring's investors include Syncona Partners, Sofinnova Partners, Gilde Healthcare, Forbion Capital Partners, British Patient Capital.

When was Purespring founded?

Purespring was founded in 2020.

Where is Purespring headquartered?

Purespring is headquartered in London, United Kingdom.

What industry is Purespring in?

Purespring operates in Biotech, Healthcare.

How many employees does Purespring have?

Purespring has 11-50 employees.

Purespring

London, United Kingdom · Founded 2020 · $165.0M raised

Biotech

Healthcare

Headquarters: London
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: purespringtx.com
Total Funding: $165.0M
Last Round: $105.0M Series BOct 2024
Rounds: 2

About

Purespring Therapeutics is a clinical-stage biotechnology company pioneering gene therapy delivery for kidney diseases, with a proprietary adeno-associated viral (AAV) platform that targets podocytes — specialized kidney cells implicated in approximately 60% of renal diseases. Founded in 2020 and headquartered in London, the company is developing precisely targeted, low-dose therapies for conditions such as IgA nephropathy (IgAN) that aim to prevent renal failure and eliminate the need for dialysis or transplantation. Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte via AAV gene therapy. The company has raised over $165 million across two funding rounds backed by leading life science investors.

Summary

Purespring is a Biotech company based in London, United Kingdom, founded in 2020. It has raised $165.0M in total across 2 rounds, most recently a $105.0M Series B round in Oct 2024. Investors include Syncona Partners, Sofinnova Partners and Gilde Healthcare.